Pharmacogenomics of multiple sclerosis: Association of immune response gene polymorphisms with copaxone treatment efficacy

Molecular Biology

Volumn 45, Issue 6, 2011, Pages 886-893

  Tsareva, E Yu ^a,b   Kulakova, O G ^a,b   Makarycheva, O Yu ^b   Boyko, A N ^a,c   Shchur, S G ^c   Lashch, N Yu ^a,c   Popova, N F ^a,c   Gusev, E I ^a   Bashinskaya, V V ^a   Lvov, D V ^d   Favorov, A V ^d,e   Ochs, M F ^e   Favorova, O O ^a,b  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^c Moscow City Multiple Sclerosis Center   (Russian Federation)

^d STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APSampler; autoimmune inflammation; copaxone; cytokines; DNA; genes; glatiramer acetate; human; multiple sclerosis; PCR; pharmacogenomics; Russians; SNP

Indexed keywords

EID: 82655189351     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1134/S0026893311060185     Document Type: Article

References (28)

1. Bruck W. 2005. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J. Neurol. 252. Suppl. 5, V3-V9.
2. Prat A., Antel J. 2005. Pathogenesis of multiple sclerosis. Curr. Opin. Neurol. 18, 225-230.
3. Khan O. A., Tselis A. C., Kamholz J. A., Garbern J. Y., Lewis R. A., Lisak R. P. 2001. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur. J. Neurol. 8, 141-148.
4. Boiko A. N., Davydovskaia M. F., Demina T. L., Lashch N. Yu., Ovcharov V. V., Popova N. F., Sinbukhova N. I., Khachanova N. V., Shchur S. G., Gusev E. I. 2006. The results of longitudinal use of copaxone and betaferon in Moscow Multiple Sclerosis Center: Issues of efficacy and adherence to therapy. Zh. Nevrol. Psikhiatr. Im S S Korsakova. Spec. no. 3, 101-110.
5. Dhib-Jalbut S. 2002. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 58(Suppl. 4), S3-S9.
6. Gusev E. I., Boiko A. N. 2004. Pathogenetic treatment of multiple sclerosis. In: Rasseyannyi skleroz i drugie demieliniziruyushchie zabolevaniya (Multiple Sclerosis and Other Demyelinating Diseases). Moscow: Miklosh, pp. 357-384.
7. Freedman M. S. 2006. Disease-modifying drugs for multiple sclerosis: Current and future aspects. Expert. Opin. Pharmacother. 7(Suppl. 1), S1-S9.
8. Tullman M. J., Lublin F. D., Miller A. E. 2002. Immunotherapy of multiple sclerosis: Current practice and future directions. J. Rehabil. Res. Dev. 39(2), 273-285.
9. Comi G., Filippi M., Wolinsky J. S. 2001. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49(3), 290-297.
10. Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J., Lisak R. P., Myers L. W., Panitch H. S., Rose J. W., Schiffer R. B. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multi-center, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 45(7), 1268-1276.
11. Fusco C., Andreone V., Coppola G., Luongo V., Guerini F., Pace E., Florio C., Pirozzi G., Lanzillo R., Ferrante P., Vivo P., Mini M., Macri M., Orefice G., Lombardi M. L. 2001. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology. 57(11), 1976-1979.
12. Gross R., Healy B. C., Cepok S., Chitnis T., Khoury S. J., Hemmer B., Weiner H. L., Hafler D. A., De Jager P. L. 2010. Population structure and HLA-DRB1*1501 in the response of subjects with multiple sclerosis to firstline treatments. J. Neuroimmunol. doi 10. 1016/j. jneuroim. 2010. 10. 038.
13. Grossman I., Avidan N., Singer C., Goldstaub D., Hayardeny L., Eyal E., Ben-Asher E., Paperna T., Pe'er I., Lancet D., Beckmann J. S., Miller A. 2007. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet. Genomics. 17(8), 657-766.
14. Alifirova V. M., Orlova Yu. Yu., Babenko S. A., Rudko A. A., Puzyrev V. P. 2006. The 1188 A/C ILI2B gene polymorphism in patients with multiple sclerosis and in healthy subjects of Tomsk region. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova. Spec. no. 3, 130-135.
15. McDonald W. I., Compston A., Edan G., Goodkin D., Hartung H. P., Lublin F. D., McFarland H. F., Paty D. W., Polman C. H., Reingold S. C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B. Y., Wolinsky J. S. 2001. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50(1), 121-127.
16. Sambrook J., Fritsch E. F., Maniatis T. 1989. Molecular Cloning. Ed. Nolan C. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press.
17. Sudomoina M. A., Boiko A. N., Demina T. L., Gusev E. I., Boldyreva M. N., Trofimov D. Yu., Alekseev L. P., Favorova O. O. 1998. Connection of multiple sclerosis in the Russian population with alleles of the major histocompatibility complex DRB1 gene. Mol. Biol. (Mosow). 32(2), 255-260.
18. He B., Navikas V., Lundah J., Söderström M., Hillert J. 1995. Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. J. Neuroimmunol. 63, 143-147.
19. Sudomoina M. A., Sukhinina T. S., Barsova R. M., Favorov A. V., Shakhnovich R. M., Titov B. V., Matveeva N. A., Rybalkin I. N., Vlasik T. N., Ochs M. F., Ruda M. Ya., Favorova O. O. 2010. Complex analsis of association of inflammation genes with myocardial infarction. Mol. Biol. (Moscow). 44(3), 407-414.
20. Makarycheva O. Yu., Tsareva E. Yu., Sudomoina M. A., Kulakova O. G., Bykova O. V., Gol'tsova N. V., Kuzenkova L. M., Boiko A. N., Favorova O. O. 2010. Linkage and association of proinflammatory cytokines genes IL6, IFNG and TNF with multiple sclerosis. Mol. Biol. (Moscow). 44, 728-733.
21. Pravica V., Perrey C., Stevens A., Lee J. H., Hutchinson I. V. 2000. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: Absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum. Immunol. 61(9), 863-866.
22. Marron M. P., Raffel L. J., Garchon H. J., Jacob C. O., Serrano-Rios M, Martinez Larrad M. T., Teng W. P., Park Y., Zhang Z. X., Goldstein D. R., Tao Y. W., Beaurain G., Bach J. F., Huang H. S., Luo D. F., Zeidler A., Rotter J. I., Yang M. C., Modilevsky T., Maclaren N. K., She J. X. 1997. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum. Mol. Genet. 6(8), 1275-1282.
23. Sandford A. J., Pare P. D. 1997. Direct PCR of small genomic DNA fragments from serum. Biotechniques. 23(5), 890-892.
24. Favorov A. V., Andreewski T. V., Sudomoina M. A., Favorova O. O., Parmigiani G., Ochs M. F. 2005. A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans. Genetics. 171(4), 2113-2121.
25. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. 1985. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog. Cardiovasc. Dis. 27(5), 335-371.
26. Favorova O. O., Kulakova O. G., Boiko A. N. 2010. Multiple sclerosis as a polygenic disease: An update. Russ. J. Genet. 46(3), 265-275.
27. Barcellos L. F., Sawcer S., Ramsay P. P., Baranzini S. E., Thomson G., Briggs F., Cree B. C., Begovich A. B., Villoslada P., Montalban X., Uccelli A., Savettieri G., Lincoln R. R., DeLoa C., Haines J. L., Pericak-Vance M. A., Compston A., Hauser S. L., Oksenberg J. R. 2006. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum. Mol. Genet. 15(18), 2813-2824.
28. Simpson J., Rezaie P., Newcombe J., Cuzner M. L., Male D., Woodroofe M. N. 2000. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J. Neuroimmunol. 108(1-2), 192-200.